Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

344
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
344
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

271
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
271
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

321
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
321
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

557
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
557
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

573
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
573
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

297
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
297

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Pregnancy and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

Journal of the American Society of Nephrology : JASN·2026
Same author

Overweight and Obesity Are Associated with Lower Renal Blood Flow in Autosomal Dominant Polycystic Kidney Disease.

Kidney & blood pressure research·2026
Same author

KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

Renal blood flow and progression to kidney failure in ADPKD.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Translational studies of chronic supplementation with a mitochondria-targeted antioxidant to improve physical function with ageing.

The Journal of physiology·2026
Same author

The authors reply.

Kidney international·2026
Same journal

Approach to Hyperkalemia: The Role of Diet and Pharmacological Therapies.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

High Protein Diets: What to Tell Our Patients.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Progressive Kidney Dysfunction and Ocular Clues: A Quiz.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Influence of Lactate Dehydrogenase on the Measurement of Blood Bicarbonate.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Urinary CXCL9 and CXCL10, Interstitial Inflammation and Disease Activity Over Time in Acute Interstitial Nephritis.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Hemophagocytic Lymphohistiocytosis and Fibroblast Growth Factor 23 (FGF23)-Induced Hypophosphatemia.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
查看所有相关文章

相关实验视频

Updated: Jan 17, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

2.2K

在CKD中准炎症

Kristen L Nowak1, Michel Chonchol1

  • 1Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

American journal of kidney diseases : the official journal of the National Kidney Foundation
|September 18, 2025
PubMed
概括
此摘要是机器生成的。

针对慢性炎症途径显示出减缓病进展和降低慢性病患者心血管疾病风险的前景. 目前正在进行的试验正在研究抗细胞因子治疗等疗法.

关键词:
抗细胞因子治疗是一种抗细胞因子疗法.在NLRP3炎症酶体中,NLRP3炎症慢性脏疾病 慢性脏疾病临床试验是指临床试验中的临床试验.这是一种炎症炎症炎症炎症.互白素-1-1的使用情况.互乐金-6是其中的一种.

更多相关视频

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.5K
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.7K

相关实验视频

Last Updated: Jan 17, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

2.2K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.5K
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.7K

科学领域:

  • 免疫学 免疫学 免疫学
  • 腎臟病學 (nephrology) 是一種醫學.
  • 心脏病学 心脏病学

背景情况:

  • 由天生的免疫激活驱动的慢性系统性炎症显著导致慢性病 (CKD) 和其并发症,包括动脉样硬化和心血管疾病 (CVD).
  • 向炎症途径代表了过去15年来研究的新型治疗策略,旨在减轻CKD患者的心血管疾病风险,并减缓病的进展.

研究的目的:

  • 审查当前和新兴的抗炎治疗策略,以管理慢性病和相关心血管风险.
  • 突出正在进行的临床试验,调查CKD患者炎症途径内的新目标.

主要方法:

  • 对最近和正在进行的临床试验的审查,重点是针对慢性病患者的特定炎症媒介和通路.
  • 检查治疗方法,包括介质素-1 (IL-1) 和IL-1受体抑制剂,介质素-6 (IL-6) 和IL-6受体抑制剂,NLRP3炎症酶抑制剂,核因素红色素2相关因子2 (Nrf2) 激活剂和老化剂.

主要成果:

  • 几种抗炎标,包括IL-1,IL-6,NLRP3炎酶,Nrf2和老化剂,正在为CKD患者的临床试验中进行积极的研究.
  • 这些试验旨在评估这些新型治疗方法在降低动脉样硬化心血管疾病风险和减缓病进展方面的疗效.

结论:

  • 针对炎症通路提供了一个有前途的途径,用于管理CKD及其心血管并发症.
  • 尽管有前途的研究,这些抗生素治疗的临床实施仍然存在挑战和考虑,正在进行的第三阶段试验的结果尚未公布.